Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – a plain language summary

Antonio González-Martín & Bradley J Monk et al. · 2024-03-19

Authors
Antonio González-Martín, Bhavana Pothuri, Ignace Vergote, Whitney Graybill, Domenica Lorusso, Colleen C McCormick, Gilles Freyer, Floor Backes, Florian Heitz, Andrés Redondo, Richard G Moore, Christof Vulsteke, Roisin E O'Cearbhaill, Izabela A Malinowska, Luda Shtessel, Natalie Compton, Mansoor R Mirza, Bradley J Monk
Funding
Pathology

NCI NIH HHS

P30 CA008748